Christopher Barrios

Also affiliated with Saint Louis University

MedicineEngineering

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials”.

Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials

The Lancet Respiratory Medicine(2025)10.1016/s2213-2600(24)00411-9

N/A

1.9DataRank · unranked

95 citations

Lael M. Yonker, F. Vermeulen, Dario Prais, Rachel W. Linnemann, Aaron Trimble +92 more

Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials

The Lancet Respiratory Medicine(2023)10.1016/s2213-2600(22)00504-5

N/A

1.5DataRank · unranked

67 citations

Gordon MacGregor, Pilar Azevedo, V. Indihar, Claire Keating, Marcus Mall +77 more